Legend Biotech Corp. (LEGN)
18.57
-0.75
(-3.88%)
USD |
NASDAQ |
Oct 02, 16:00
18.57
0.00 (0.00%)
After-Hours: 20:00
Legend Biotech Enterprise Value : 2.912B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 2.912B |
| October 01, 2026 | 3.057B |
| September 30, 2026 | 3.168B |
| September 29, 2026 | 2.960B |
| September 28, 2026 | 2.922B |
| September 25, 2026 | 3.017B |
| September 24, 2026 | 3.007B |
| September 23, 2026 | 2.889B |
| September 22, 2026 | 2.925B |
| September 21, 2026 | 2.904B |
| September 18, 2026 | 2.726B |
| September 17, 2026 | 2.720B |
| September 16, 2026 | 2.608B |
| September 15, 2026 | 2.737B |
| September 14, 2026 | 2.904B |
| September 11, 2026 | 2.925B |
| September 10, 2026 | 3.032B |
| September 09, 2026 | 3.172B |
| September 08, 2026 | 3.284B |
| September 04, 2026 | 3.483B |
| September 03, 2026 | 3.528B |
| September 02, 2026 | 3.555B |
| September 01, 2026 | 3.408B |
| August 31, 2026 | 3.340B |
| August 28, 2026 | 3.166B |
| Date | Value |
|---|---|
| August 27, 2026 | 3.286B |
| August 26, 2026 | 3.321B |
| August 25, 2026 | 3.441B |
| August 24, 2026 | 3.371B |
| August 21, 2026 | 3.542B |
| August 20, 2026 | 3.433B |
| August 19, 2026 | 3.693B |
| August 18, 2026 | 3.561B |
| August 17, 2026 | 3.315B |
| August 14, 2026 | 3.261B |
| August 13, 2026 | 3.241B |
| August 12, 2026 | 3.315B |
| August 11, 2026 | 3.544B |
| August 10, 2026 | 3.317B |
| August 07, 2026 | 3.334B |
| August 06, 2026 | 3.049B |
| August 05, 2026 | 3.005B |
| August 04, 2026 | 3.020B |
| August 03, 2026 | 2.997B |
| July 31, 2026 | 2.908B |
| July 30, 2026 | 3.005B |
| July 29, 2026 | 2.966B |
| July 28, 2026 | 3.003B |
| July 27, 2026 | 3.048B |
| July 24, 2026 | 3.619B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 200.90B |
| Ionis Pharmaceuticals, Inc. | 7.346B |
| Johnson & Johnson | 644.86B |
| Arbutus Biopharma Corp. | 790.47M |
| Capricor Therapeutics, Inc. | 373.19M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 33.25M |
| Revenue (Quarterly) | 388.14M |
| Total Expenses (Quarterly) | 354.89M |
| EPS Diluted (Quarterly) | 0.1716 |
| Gross Profit Margin (Quarterly) | 61.52% |
| Profit Margin (Quarterly) | 8.57% |
| Earnings Yield | -2.72% |
| Normalized Earnings Yield | -2.655 |